MMandC Revenue and Competitors

UK

Location

N/A

Total Funding

PR/Comm

Industry

Estimated Revenue & Valuation

  • MMandC's estimated annual revenue is currently $2.7M per year.(i)
  • MMandC's estimated revenue per employee is $140,400

Employee Data

  • MMandC has 19 Employees.(i)
  • MMandC grew their employee count by 36% last year.

MMandC's People

NameTitleEmail/Phone
1
Owner/Managing DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$14.7M70-3%N/AN/A
#2
$12.8M610%N/AN/A
#3
$20.8M899%N/AN/A
#4
$0.2M2-33%N/AN/A
#5
$60.2M234N/AN/AN/A
#6
$4.1M25N/AN/AN/A
#7
$62.3M242-1%N/AN/A
#8
$141.6M484N/AN/AN/A
#9
$18.7M8023%N/AN/A
#10
$2.7M19-41%N/AN/A
Add Company

What Is MMandC?

MM&C was founded in 1998 and since then we have earned a reputation for continued professional performance with some of the leading companies in the Isle of Man. Our portfolio reflects the Island’s diverse economy, covering sectors including Government, financial services, telecommunications, pharmaceuticals, e-gaming and e-business.

keywords:N/A

N/A

Total Funding

19

Number of Employees

$2.7M

Revenue (est)

36%

Employee Growth %

N/A

Valuation

N/A

Accelerator

MMandC News

2022-04-17 - MM 4.21: No. 24 Maryland baseball’s Bobby Zmarzlak named Big Ten player of the Week

Bobby Zmarzlak was named the Big Ten Player of the Week, the conference announced on Tuesday. Zmarzlak has been on a tear his last few games...

2022-04-17 - MM 4.22: Six Terps lacrosse stars nominated for 2022 Tewaaraton Award

Maryland's men's and women's lacrosse teams combined for six players who were named to the 25-player Tewaaraton Award nominee list,...

2022-04-17 - Mesenchymal Stem Cells Induce Cell Proliferation, Inhibit ...

MM is a hematological malignancy that weakens bone tissue, causes fractures, and negatively affects the immune system. For most patients, it is...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M19-39%N/A
#2
$1.7M19-5%N/A
#3
$1.2M190%N/A
#4
N/A190%N/A
#5
$1.7M19N/AN/A